Cisplatin Plus S-1
Short Hydration in Chemotherapy with Cisplatin plus S 1 for Advanced or Recurrent Gastric Cancer: A Retrospective Study
... Another study compared 30 patients with gastric cancer, lung cancer, and the urothelial cancer who received outpatient chemotherapy containing CDDP ≥60 mg/m2/cycle with short hydration r[r] ...
8
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
... of S-1 have been reported to be more severe in individuals from USA than those from Asian, indicating different dosage recommended for these populations [13, ...that S-1 plus ...
9
The Outcome of Treatment for Patients with Borrmann Type 4 Advanced Gastric Cancer
... 1990s, S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan), an oral derivative of 5-FU, was developed for the treatment of gastric cancer [13] ...Japan, S-1 rapidly established itself as a ...
10
Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
... Japan; 1: 20) and MET (anti-c-Met rabbit polyclonal antibody; Invitrogen, Carlsbad, CA, USA; 1: ...Conditioning 1; ...30 s and 90°C for 10 s for FGFR2 and MET ...
9
Original Article Correlation of β-tubulin III and ERCC1 mRNA expression to chemotherapy outcome of gastric cancer patients with malignant ascites
... or cisplatin (DDP) plus tegafur-gimeracil-oteracil potassium (S-1) related to the expression levels of two genes, TUBB3 and ERCC1, when given to gastric cancer patients with peritoneal ...
8
Feasibility of Outpatient Chemotherapy with S 1 and Cisplatin for Gastric Cancer
... high-dose cisplatin regimen usually requires at least three days of administration, giving a medical cost in Japan of at least US $1200 for every ...high-dose cisplatin in combination with aprepitant ...
8
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta analysis
... the 1-year survival ...the 1-year survival of two studies might be due to the fact that the combination group of the Banu study contained different ...Gem plus cisplatin is recommended over ...
9
<p>Peripheral Blood Platelet–Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients</p>
... years. 1 – 3 The JCOG0405 (Japan Clinical Oncology Group) study reported the safety of S-1 plus cisplatin treatment as preoperative chemotherapy followed by D2 gastrectomy with ...
9
Successful conversion surgery for gastric cancer with multiple liver metastases treated after S-1 plus cisplatin combination chemotherapy: a case report
... Since the patient rejected our suggestion for a con- version surgery, 12 more courses of this regimen and 4 courses of S-1 (S-1, 80 mg/m 2 ) were adminis- tered. The relative dose intensities ...
5
Ribonucleotide reductase inhibition restores platinum sensitivity in platinum resistant ovarian cancer: a Gynecologic Oncology Group Study
... ’ s minimum essential medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum, 1% non-essential amino acids and 1% penicillin/streptomycin was ...used. Cisplatin and ...
10
Effects of Pluchea lanceolata Root Extract on Cisplatin induced Nausea and Vomiting in Rat Pica Model
... Effect of cisplatin (3 mg/kg) and cisplatin plus MPL (200 and 400 mg/kg) on reduced food intake (% baseline) induced by cisplatin in rats. Values are expressed as mean ± SD.[r] ...
5
Role of Chemotherapy in Advanced Gastric Cancer: Review from a Latin American Perspective
... and cisplatin 50 mg/m 2 every 2 weeks (FLP ...to cisplatin for the treatment of advanced GC in these pa- tients ...days 1 and 2 and oxaliplatin 85 mg/m 2 on day 1 every 2 weeks), a regimen ...
12
Update on first-line treatment of advanced ovarian carcinoma
... In the bevacizumab arm, there was an improvement in median progression-free survival from 17.3 to 19.0 months (HR for progression or death with bevacizumab added, 0.81; 95% CI 0.70–0.94; P = 0.004 by the log-rank test). ...
7
How I treat gastric adenocarcinoma
... perioperative cisplatin plus 5-FU in a 28-day regimen, although it included a greater proportion of patients with proximal tumours, compared with the MAGIC ...of cisplatin and 5-FU demonstrated an ...
6
Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
... criteria: 1) aged 18–75 years at diag- nosis; 2) a histologically proven unresectable advanced or metastatic lesion; 3) an Eastern Cooperative Oncology Group ...
7
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis
... Docetaxel was first approved by the US Food and Drug Administration (FDA) in 1996 for use in metastatic breast cancer, but shortly thereafter garnered indications for first and second-line use in NSCLC. Below we review ...
14
Management of Hematologic Toxicity in Patients with Advanced or Metastatic Gastric Cancer Treated with Docetaxel, Cisplatin and Fluorouracil (DCF): Results of Monocentric Experience
... Gastric cancer is one of the most frequent malignancies in Europe since the fifth cancer incidence for both the male and in female. Over the past decades, the epidemiology of gastric cancer has been profoundly modified ...
5
Updates in oncology
... A systematic review of lung cancer screening using low-dose computed tomography (LDCT) has been reported by a group of US medical societies [8], taking into account the recently published National Lung Screening Trial ...
10
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
... CI: 0.74–0.96, P = 0.01). PFS was also statistically significant favoring the necitumumab arm 5.7 vs 5.5 months (HR = 0.84, 95% CI: 0.75–0.95, P = 0.006). The overall response rate was 31.2% in the necitumumab arm vs ...
7
Melatonin as a potential anticarcinogen for non-small-cell lung cancer
... in melatonin circadian rhythm result in chronodisruption which is associated with many health disorders including heart diseases, neurodegenerative diseases, and cancer [11, 45]. Epidemiological studies have demonstrated ...
17